ALKS vs UNH

ALKS presents a stark dichotomy between financial stability and operational growth. While the deterministic health is strong, evidenced by a Piotroski F-Score of 8/9 and a negligible Debt/Equity ratio of 0.04, the company is suffering from severe earnings contraction (-67% YoY) and negative revenue growth. The stock trades at a significant premium to both its Graham Number ($18.8) and Intrinsic Value ($10.01), suggesting the current price is driven by analyst optimism rather than current fundamentals. Despite a 'strong_buy' analyst consensus, insider selling and a deteriorating forward P/E indicate significant valuation risk.

UnitedHealth Group presents a conflicted profile with a stable but mediocre Piotroski F-Score of 4/9 and a significant disconnect between current price ($323.48) and defensive fair value (Graham Number: $175.91). While revenue growth remains robust at 12.3%, the company has suffered a catastrophic collapse in YoY earnings growth (-99.9%), suggesting severe short-term headwinds or one-time accounting shocks. Technical trends are currently bearish (0/100), though a recent one-month bounce and a favorable Forward P/E of 16.08 indicate analyst expectations of a recovery. The stock is currently trading at a significant premium to its intrinsic value, relying heavily on its market dominance and future earnings normalization.